
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023

Incepta Pharmaceuticals Ltd. · Tablet
/ Piece
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Phenobarbital is indicated for the following conditions:
Sedatives
Hypnotics for the short-term treatment of insomnia
Pre-anesthetics
Long-term anticonvulsants for the treatment of generalized tonic-clonic and cortical local seizures. And, in the emergency control of certain acute convulsive episodes, (those associated with status epilepticus, eclampsia meningitis, tetanus, and toxic reactions to Strychnine or local anesthetics).
Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal). Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.
Suggested doses of Phenobarbital for specific indications are as follows:Pediatric Oral Dosage:
Preoperative: 1 mg to 3 mg/kg.
Anticonvulsant: 1 mg to 6 mg/kg per day
Adult Oral Dosage:
Daytime sedative: 30 mg to 120 mg daily in 2 to 3 divided doses.
Bedtime hypnotic: 100 mg to 320 mg.
Anticonvulsant: 50 mg to 100 mg 2 to 3 times daily.
Pediatric Injection Dosage:
15 to 20 mg/kg IV over 10 to 15 min.
Preoperative Sedation:1 to 3 mg/kg IM/IV;
Anticonvulsant: 4 to 6 mg/kg IM/IV per day, for 10 days. Alternatively, use 10 to 15 mg/kg IM/IV per day to reach therapeutic level more quickly. Maxium IV rate 60 mg/min.
Adult Injection Dosage:
Insomnia: 100 to 320 mg IM/IV;
Convulsions: 100 to 320 mg IV. Repeat if needed (maximum, 600 mg per day);
Status Epilepticus: 10 to 20 mg/kg IV. Repeat if needed.
The concomitant use of Alcohol or other CNS depressants may produce additive CNS depressant effects.
The most common adverse reaction is somnolence. Other less frequent adverse reactions are agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality, apnea, bradycardia, hypotension, nausea, vomiting and constipation.
Pregnancy Category D. Phenobarbital can cause fetal damage when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be in risk of the potential hazard to the fetus. Caution should be taken when Phenobarbital is administered to a nursing woman since small amounts of Phenobarbital are excreted in the milk.
Tolerance and psychological and physical dependence may occur with continuing use. Phenobarbital should be administered with caution to patients who are mentally depressed, have suicidal tendencies, or a history of drug abuse. In patients with hepatic damage, Phenobarbital should be administered with caution and initially reduced doses.
Adjunct anti-epileptic drugs, Barbiturates
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.